EGFR and lung adenocarcinoma: Therefore, our study aimed to explore whether a radiomics signature encompassing intra- and peri-tumoral radiomics features from time-serial CT can accurately predict PFS and early stratify the risk of acquired resistance for lung adenocarcinoma patients undergoing EGFR-TKI treatment.